Physical Therapists in Los Ranchos, NM Accepting Medicare

6 Physical Therapists found. Showing 1 - 6

Something's Moving, Inc. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6902 4th St Nw, Suite A, Los Ranchos, NM 87107 Phone: 505-345-3909    Fax: 505-345-0099

Alexander George Sfakianos Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 315 Pueblo Solano Rd Nw, Los Ranchos, NM 87107 Phone: 505-314-3173

Frank Brady, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4132 Dietz Farm Cir Nw, Los Ranchos, NM 87107 Phone: 505-440-6915

Dr. Tatenda Chibanga, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 808 Chamisal Rd Nw, Los Ranchos, NM 87107 Phone: 505-720-9049

Nm Pelvic Health Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7013 4th St Nw Ste I, Los Ranchos, NM 87107 Phone: 505-369-6656

Dr. Felicia Chaves, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7013 4th St Nw Ste I, Los Ranchos, NM 87107 Phone: 505-369-6656

News Archive

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).

Multiple toxic mechanisms link elevated iron, copper levels in the brain and extensive DNA damage

No one knows the cause of most cases of Alzheimer's, Parkinson's and other neurodegenerative disorders. But researchers have found that certain factors are consistently associated with these debilitating conditions.

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

Allen Institute for Brain Science receives $8.7 million NIH grant to explore synapses

The Allen Institute for Brain Science, in a project led by Stephen Smith, Ph.D., Senior Investigator, has been awarded an $8.7 million, five-year Transformative Research Award from the National Institutes of Health to lead the creation of a publicly accessible model of synapse populations in mouse and human brains.

Read more Medical News

› Verified 8 days ago